biotech.today

Details

  • ●Modalities: small molecules, natural products
  • ●Therapeutic areas: obesity, inflammation, pain
  • ●Key targets:
  • ●Indications: Undisclosed
  • ●Funding: $55M

Partners & investors

  • NVIDIA· Investor

Key considerations

  • ●AI tools in use: Prism Platform
  • ●$55M Series B (2023)
  • ●Backed by Nvidia, FPV, True Ventures

Pipeline

  • Phase 11
Get live updates on Enveda Biosciences’s hiring, filings, and partnerships. Follow in BT Pro →
Source: Company website, SEC / Companies House filings, press releases, Crunchbase · biotech.today analysis (Apr 2026)

Key people

Viswa Colluru

Co-Founder & CEO

natural-productsml-drug-discovery
Visit website →LinkedIn →